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Aims Coxsackievirus B3 (CVB3)-induced myocarditis, initially considered a sole immune-mediated disease, also results
from a direct CVB3-mediated injury of the cardiomyocytes. Mesenchymal stem cells (MSCs) have, besides immuno-
modulatory, also anti-apoptotic features. In view of clinical translation, we ﬁrst analysed whether MSCs can be
infected by CVB3. Next, we explored whether and how MSCs could reduce the direct CVB3-mediated cardiomyo-
cyte injury and viral progeny release, in vitro, in the absence of immune cells. Finally, we investigated whether MSC
application could improve murine acute CVB3-induced myocarditis.
Methods
and results
Phase contrast pictures and MTS viability assay demonstrated that MSCs did not suffer from CVB3 infection 4–12–
24–48 h after CVB3 infection. Coxsackievirus B3 RNA copy number decreased in this time frame, suggesting that no
CVB3 replication took place. Co-culture of MSCs with CVB3-infected HL-1 cardiomyocytes resulted in a reduction
of CVB3-induced HL-1 apoptosis, oxidative stress, intracellular viral particle production, and viral progeny release in a
nitric oxide (NO)-dependent manner. Moreover, MSCs required priming via interferon-g (IFN-g) to exert their pro-
tective effects. In vivo, MSC application improved the contractility and relaxation parameters in CVB3-induced myo-
carditis, which was paralleled with a reduction in cardiac apoptosis, cardiomyocyte damage, left ventricular tumour
necrosis factor-a mRNA expression, and cardiac mononuclear cell activation. Mesenchymal stem cells reduced the
CVB3-induced CD42 and CD82 T cell activation in an NO-dependent way and required IFN-g priming.
Conclusion We conclude that MSCs improve murine acute CVB3-induced myocarditis via their anti-apoptotic and immunomo-
dulatory properties, which occur in an NO-dependent manner and require priming via IFN-g.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Myocarditis is a common inﬂammatory cardiomyopathy which can
lead to a chronic impaired left ventricular (LV) function. Many
different infectious agents have been considered the cause of
viral myocarditis, including enteroviruses, adenovirus, cytomegalo-
virus, hepatitis C virus, parvovirus B19, and others. Among the
most commonly identiﬁed infectious agents are the coxsackie B
viruses (CVB), members of the enteroviral family. A direct
CVB3-mediated injury of the cardiomyocytes in infected hearts
1,2
as well as cardiac inﬂammation
3 underlies CVB3-induced viral
myocarditis.
Under present pharmacological treatment, which is mainly
focused on decreasing the activity of the neuroendocrine system,
the prognosis against virus-induced inﬂammatory cardiomyopathy
is not improved. This might be due to the lack of effects on the
direct virus-induced components of the disorder. Therefore, differ-
ent strategies, including gene therapeutic approaches and
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anti-viral directed immune response,
4 are under investigation in
experimental
5 and/or clinical studies.
6
There is accumulating experimental
2 and clinical support
7,8 for
the application of cellular transplantation as a strategy to
improve myocardial function. Mesenchymal stem cells (MSCs)
have anti-apoptotic,
9 anti-ﬁbrotic,
10 and pro-angiogenic
11 features.
They have the advantage over other stem cells that they are non-
immunogenic, enabling the use of allogeneic MSCs for clinical appli-
cation.
8 Moreover, MSCs have immunomodulatory properties,
12
which make them an attractive cell source for the treatment of
virus-induced inﬂammatory cardiomyopathy, given the importance
of the inﬂammatory component in this disorder. Among others,
MSCs suppress T cell responses,
13,14 induce apoptosis of activated
T cells,
15 and increase T regulatory cells.
16 Interferon-g (IFN-g) has
been shown to play an important role in priming MSC-mediated
immunoregulatory effects
12,17 as well as in inducing nitric oxide
(NO) production in MSCs.
18 On the other hand, NO exerts anti-
apoptotic effects on cardiomyocytes
19,20 and has anti-viral proper-
ties.
21 Moreover, MSCs have been shown to exert their immuno-
modulatory effects in an NO-dependent manner.
12
The present study focuses at investigating whether MSCs are
potential candidates for the treatment of acute CVB3-induced
inﬂammatory cardiomyopathy. In view of clinical translation, the
safety aspect whether MSCs can be infected by CVB3 is investigated.
In addition, the study focuses at evaluating whether and how MSCs
can (i) reduce the direct CVB3-mediated cardiomyocyte injury in
vitro, and (ii) decrease cardiac apoptosis and improve LV function
in an experimental model of murine acute CVB3-induced myocar-
ditis. Furthermore, the role of NO and of IFN-g priming in the
MSC-mediated protective effects is investigated.
Methods
For detailed methodology, please see Supplementary material online.
Human adult MSCs were isolated from iliac crest bone marrow aspi-
rates of normal male donors (n ¼ 6) after their written approval.
Mesenchymal stem cells were characterized by ﬂow cytometry analysis
according to Binger et al.
22 To investigate whether MSCs can be
infected with CVB3, MSCs were serum starved or exposed to CVB3
at a multiplication of infection (m.o.i.) of 5 for 1 h under serum-
starvation conditions. Next, cell morphology, cell viability, and CVB3
RNA copy number were evaluated 4, 12, 24, and 48 h after serum star-
vation/infection via phase contrast pictures, MTS viability assay, and
real-time PCR, respectively. Next, to determine whether MSCs can
protect against direct CVB3-induced cardiomyocyte damage, MSCs
were co-cultured with uninfected or CVB3-infected HL-1 cardiomyo-
cytes at a ratio of 1 MSC to 10 HL-1. The effect of MSC supplemen-
tation on CVB3-induced HL-1 cardiomyocyte apoptosis, oxidative
stress, virion progeny release, and intracellular virion production was
determined via annexin V/7AAD ﬂow cytometry and caspase 3/7
activity analysis, DCF ﬂow cytometry, and plaque assay, respectively.
To analyse whether the MSC-mediated effects were NO dependent,
MSCs were pre-treated with nitro-L-argininmethylesterhydrochloride
(L-NAME) for 24 h. To investigate whether MSCs require IFN-g to
exert their protective effects, MSCs were co-cultured with uninfected
or CVB3-infected HL-1 cells in the presence of 1 mg/mL of anti-murine
IFN-g antibody. NOx and IFN-g levels in HL-1 monocultures as well as
in co-cultures with MSCs were analysed. Furthermore, the effect of
IFN-g supplementation on NOx production in uninfected or
CVB3-infected MSCs was evaluated.
In vivo,1 0
6 MSCs or phosphate buffered saline (PBS) was i.v.
injected
23 in 6–8-week-old C57BL/6 mice 1 day after i.p. infection
with 5 × 10
5 plaque-forming units of CVB3 (Nancy strain). Controls
received PBS instead of CVB3. Seven days after CVB3 infection, con-
tractility parameters were analysed as described previously.
24 Left ven-
tricular damage, apoptosis, and tumour necrosis factor-a (TNF-a)
mRNA expression were determined via haematoxylin eosin staining,
TUNEL staining, and real-time PCR, respectively. Furthermore, the
effect of MSC application on cardiac mononuclear cell (MNC) prolifer-
ation/activation was evaluated via isolation of cardiac MNCs, followed
by carboxyﬂuorescein succinimidyl ester-staining and ﬂow cytometry.
Finally, it was evaluated how MSCs reduce the proliferation of
CVB3-induced CD42 and CD82 T cell proliferation via (co)-culture
of carboxyﬂuorescein succinimidyl ester-labelled MNCs stimulated
with inactivated CVB3, with or without MSCs (untreated or pre-
treated with L-NAME for 24 h) in the presence or absence of 1 mg/
mL of anti-murine IFN-g antibody, followed by CD4 and CD8 staining
and ﬂow cytometry. NOx and IFN-g levels in MNC monocultures as
well as in co-cultures with MSCs were analysed.
Results
Mesenchymal stem cells cannot be
infected by coxsackievirus B3
Human adult MSCs were isolated from iliac crest bone marrow
aspirates of normal male donors (n ¼ 6) after their written
approval. A representative picture of a ﬂow cytometry analysis
of MSC is shown in Supplementary material online, Figure S1.T o
investigate whether MSCs can be infected with CVB3, whether
replication of CVB3 takes place, and whether MSCs suffer from
CVB3, a time-frame experiment was performed. Phase contrast
pictures did not show any signiﬁcant changes in cell morphology
between serum-starved and CVB3-infected MSCs under serum-
starvation conditions (Figure 1A). In line with this observation, no
signiﬁcant differences were found in MSC viability between post-
infection and post-serum starvation at all time points (Figure 1B).
Coxsackievirus B3 RNA copy number, expressed as CVB3
towards L32, decreased over time in MSCs, with 4.1-fold (P ¼
0.057) and 7.2-fold (P ¼ 0.036) lower levels at 24 and 48 h post-
infection vs. 4 h post-infection, respectively (Figure 1C). No
plaques were detected on HeLa cells incubated with the medium
collected from MSCs 24 h after CVB3 infection, not at dilutions
10
25 and 10
24, neither at dilution 10
23. In addition, the inability
to infect MSCs with CVB3 was further underscored by the
ﬁnding that the beneﬁcial effects of MSCs were not impaired
after CVB3 infection compared with serum starvation (Supplemen-
tary material online, Figure S2).
Mesenchymal stem cells reduce
coxsackievirus B3-induced apoptosis
Coxsackievirus B3 targets cardiomyocytes, leading to cardiomyo-
cyte apoptosis.
2 To investigate whether MSCs exert anti-apoptotic
effects on CVB3-infected HL-1 cardiomyocytes, we co-cultured
MSCs in the presence of CVB3-infected HL-1 and performed
annexin V/7AAD FACS analysis. Phase contrast pictures showed
MSCs improve murine acute CVB3-induced myocarditis 2169that MSCs reduce the amount of CVB3-induced ﬂoating cells,
indicative for necrotic cells (Figure 2A, upper panel). In addition,
MSCs decreased the 4.2-fold (P ¼ 0.029) CVB3-induced HL-1
apoptosis to levels not signiﬁcantly different from non-infected
cells (Figure 2A, middle and lower panels). Mesenchymal stem cells
have been shown to exert immunomodulatory effects in an
NO-dependent manner and to require IFN-g priming.
12 We evalu-
ated whether these underlying mechanisms could be extrapolated
to the MSC-mediated protective effects in the context of
CVB3-infected HL-1 cells. Therefore, MSCs were pre-treated with
L-NAME or co-cultured with CVB3-infected HL-1 cells in the pres-
ence of an anti-mouse IFN-g-neutralizing antibody. Under these
conditions, the anti-apoptotic MSC-mediated effects were abro-
gated. Next, we analysed whether the MSC-mediated reduction in
HL-1 apoptosis was associated with decreased caspase 3/7 activity.
Supplementation of MSCs declined the CVB3-induced caspase 3/7
activity by 1.4-fold (P , 0.0008). This effect was abrogated when
MSCs were pre-treated with L-NAME and was less pronounced
in the presence of an anti-mouse IFN-g antibody (Figure 2B). NOx
levels were not increased in the medium of HL-1 and MSC
co-cultures compared with HL-1 monocultures, suggesting that at
a ratio of 1 MSC to 10 HL-1 cells, the increase in NO is not detect-
able (Supplementary material online, Figure S3A). Mesenchymal stem
cell supplementation did not affect murine IFN-g levels of HL-1 cells
(Supplementary material online, Figure S3B).
Mesenchymal stem cells reduce
coxsackievirus B3-induced oxidative
stress in HL-1 cardiomyocytes
Given the importance of the intracellular oxidation status in the
pathogenesis of CVB3 infections,
25 we investigated whether MSCs
exert anti-oxidative effects on CVB3-infected HL-1 cells. Therefore,
we analysed the presence of ROS in MSC-HL-1 co-cultures by
Figure 1 Mesenchymal stem cells cannot be infected by coxsackievirus B3 (CVB3). Mesenchymal stem cells were plated in a 6-well plate for
phase contrast pictures or in a 96-well plate for MTS assay, respectively. After 24 h, reaching 80% conﬂuence, mesenchymal stem cells were
serum starved or infected with coxsackievirus B3 under serum-starvation conditions at a m.o.i. of 5. Four, 12, 24, and 48 h after infection or
serum starvation, phase contrast pictures were taken or MTS assay was performed. (A) Phase contrast pictures of mesenchymal stem cells, 4,
12, 24, and 48 h after coxsackievirus B3 infection (upper panel) or serum starvation (lower panel), at ×100 magniﬁcation. (B) Bar graphs repre-
senting the absorbance at 490 nm from non-infected (open bar graphs) and coxsackievirus B3-infected (closed bar graphs) mesenchymal stem
cells 4, 12, 24, and 48 h after serum starvation or coxsackievirus B3 infection, respectively. n ¼ 6/condition. (C) Bar graphs representing cox-
sackievirus B3 copy number expressed as coxsackievirus B3 vs. L32 in coxsackievirus B3-infected (closed bar graphs) mesenchymal stem cells 4,
12, 24, and 48 h after coxsackievirus B3 infection. n ¼ 6/condition.
S. Van Linthout et al. 2170Figure 2 Mesenchymal stem cells (MSCs) reduce coxsackievirus B3-induced apoptosis in a nitric oxide-dependent way and require priming
via interferon-g (IFN-g). DiO-labelled HL-1 cells were cultured in a six-well plate and 24 h later infected with coxsackievirus B3 under serum-
starvation conditions at a m.o.i. of 5. Four hours later, MSCs were added at a ratio of 1 to 10 HL-1 cells. After 24 h, cells were collected for
annexin V/7AAD FACS analysis. (A) Upper panel shows representative pictures of non-infected HL-1, non-infected HL-1 co-cultured with
MSCs, infected HL-1, and infected HL-1 co-cultured with MSCs; middle panel demonstrates representative pictures of annexin V/7AAD dot
plots on pre-selected DiO+ HL-1 cells. Lower panel: bar graphs represent the mean+SEM of DiO+ annexin V+/7AAD- HL-1 cells in cul-
tures of HL-1 with or without untreated or L-NAME-treated MSCs or MSCs in the presence or absence of 1 mg/mL of IFN-g antibody (ab);
n ¼ 4/group. (B) Bar graphs represent the mean+SEM of caspase 3/7 activity in cultures of HL-1 with or without untreated or
L-NAME-treated MSCs or MSCs in the presence or absence of 1 mg/mL of IFN-g antibody (ab); n ¼ 6/group.
MSCs improve murine acute CVB3-induced myocarditis 2171CM-H2DCFDA ﬂow cytometry. To distinguish the presence of ROS
in HL-1 cells or MSCs in the MSC-HL-1 co-cultures, HL-1 cells were
pre-labelled with the ﬂuorescence dye Dil before plating. Flow
cytometry analysis showed that CVB3 induced ROS production in
HL-1 cells by 6.3-fold (P ¼ 0.0076) (Figure 3), whereas MSCs
reduced the increased ROS production by 5.1-fold (P ¼ 0.029)
to levels not signiﬁcantly different from non-infected controls. The
anti-oxidative effects of MSCs were abrogated when MSCs were
pre-treated with L-NAME or co-cultured in the presence of anti-
mouse IFN-g-neutralizing antibody (Figure 3).
Mesenchymal stem cells reduce viral
progeny release and intracellular viral
particle production in HL-1
cardiomyocytes
We next evaluated whether the anti-apoptotic and anti-oxidative
effects of MSCs on CVB3-infected HL-1 cells were paralleled with
a reduction in viral progeny release. Therefore, medium from
co-culture experiments was collected and plaque assay was
performed. CAPs reduced the viral progeny release by 5.1-fold
(P ¼ 0.007), an effect which was blunted in the presence of
L-NAME and by blocking murine IFN-g (Figure 4A). Further analy-
sis demonstrated that besides reducing the release of CVB3
virions, MSCs also decreased the production of intracellular
CVB3 particles in an NO-dependent manner and required
priming via IFN-g (Figure 4B).
Interferon-g increases nitric oxide in
coxsackievirus B3-infected mesenchymal
stem cells
Recently, Oh et al.
18 demonstrated that IFN-g is critical for NO
production by MSCs. Since our data indicate that MSCs exert
their protective effects on CVB3-infected HL-1 cells in an
NO-dependent manner and require IFN-g, we next investigated
Figure 3 Mesenchymal stem cell (MSCs) reduce coxsackievirus B3-induced oxidative stress in a nitric oxide-dependent way and require
priming via interferon-g (IFN-g). Dil-labelled HL-1 cells were cultured in a six-well plate and 24 h later infected with coxsackievirus B3
under serum-starvation conditions at a m.o.i. of 5. Four hours later, mesenchymal stem cells were added at a ratio of 1 to 10 HL-1 cells.
After 24 h, cells were collected for DCF FACS analysis. Upper panel demonstrates representative pictures of Dil/DCF dot plots of non-infected
HL-1, non-infected HL-1 co-cultured with MSCs, infected HL-1, and infected HL-1 co-cultured with MSCs. Lower panel: bar graphs represent
the mean+SEM of DCF+/Dil+ HL-1 cells in cultures of HL-1 with or without untreated or L-NAME-treated MSCs or with MSCs in the
presence or absence of 1 mg/mL of IFN-g antibody (ab); n ¼ 4/group.
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HL-1 cells with MSCs can lead to NO induction in MSCs. Sup-
plementation of murine IFN-g to non-infected MSCs did not
increase NO production, whereas CVB3 infection combined
with murine IFN-g administration raised NO production by
1.2-fold (P ¼ 0.031) vs. non-infected MSCs (Supplementary
material online, Figure S4).
Mesenchymal stem cells improve murine
acute coxsackievirus B3-induced
myocarditis
After evaluating in vitro whether and how MSCs can reduce the
direct CVB3-induced cardiomyocyte damage, we ﬁnally investi-
gated whether MSC application could improve murine acute
CVB3-induced myocarditis in vivo. Cardiac contractility and relax-
ation were signiﬁcantly ameliorated in MSC-treated compared
with PBS-injected CVB3-infected mice, as indicated by a 1.5-fold
(P ¼ 0.0002) and 1.7-fold (P ¼ 0.001) improvement in the con-
tractility parameters dP/dtmax and dP/dtmin, respectively (Figure 5).
This was associated with a reduction in cardiomyocyte necrosis
and ﬁbrosis, as indicated by haematoxylin and eosin staining
(Figure 6A). Furthermore, MSC application decreased the
CVB3-induced cardiac apoptosis (Figure 6B) and LV TNF-a
mRNA expression (Figure 6C) by 3.2-fold (P ¼ 0.018) and
3.2-fold (P , 0.0001), respectively.
Mesenchymal stem cells reduce cardiac
mononuclear cell activity in
coxsackievirus B3-infected mice
Finally, we analysed whether MSC application could reduce the
activity of cardiac MNCs in murine acute CVB3-induced myocar-
ditis. Therefore, cardiac MNC isolated from control and
CVB3-infected mice, injected with PBS or MSCs, was carboxy-
ﬂuorescein succinimidyl ester-labelled and cultured for 72 h in
the presence or absence of inactivated CVB3, followed by ﬂow
cytometry analysis. The amount of peaks, indicative for cell pro-
liferation, was reduced in cardiac MNCs isolated from
CVB3-infected mice receiving MSCs compared with PBS-injected
CVB3-infected mice, under unstimulated as well as stimulated con-
ditions (Figure 7A). To further evaluate how MSCs exert these anti-
proliferative effects, MNCs were isolated from the spleen from
control and CVB3-infected mice, carboxyﬂuorescein succinimidyl
ester-labelled, and next cultured with or without untreated or
L-NAME-treated MSCs, or with MSCs in the presence or absence
of 1 mg/mL of IFN-g antibody. Supplementation of MSCs to MNCs
ataratioof1to10reducedtheinactivatedCVB3-stimulateddivision
index of CD42 and CD82 T cells from CVB3-infected mice by
2.5-fold (P ¼ 0.029) and 2.5-fold (P ¼ 0.029), respectively. This
effect was less pronounced or abrogated when MSCs were pre-
treated with L-NAME or co-cultured with MNCs in the presence
of an IFN-g antibody (Figure 7B). Similar to HL-1-MSC co-cultures,
no increase in NOx levels could be observed in MNC-MSC
Figure 4 Mesenchymal stem cells (MSCs) reduce coxsackievirus B3 viral progeny release and intracellular viral particle building in a nitric
oxide-dependent way and require priming via interferon-g (IFN-g). HeLa cells were incubated for 30 min with 1 mL of diluted medium/
supernatant. Then, cells were washed with PBS and covered with agar consisting 50% of 1.3% noble agar and 50% of 2 MEM, supplemented
with 4% FBS. (A) Bar graphs represent the mean+SEM of counted plaques in six wells/condition, 72 h after incubation with 10
24 diluted
medium of cultures of coxsackievirus B3-infected HL-1 with or without untreated or L-NAME-treated MSCs or with MSCs in the presence
or absence of 1 mg/mL of IFN-g antibody (ab). (B) Bar graphs represent the mean+SEM of counted plaques in six wells/condition, 72 h
after incubation with 10
24 diluted supernatant, which is obtained after four freeze–thaw cycles of cell pellets collected 8 h post-infection
from coxsackievirus B3-infected HL-1 with or without untreated or L-NAME-treated MSCs or with MSCs in the presence or absence of
1 mg/mL of IFN-g ab.
MSCs improve murine acute CVB3-induced myocarditis 2173co-culturescomparedwithMNCmonocultures,suggestingthatata
ratio of 1 MSC to 10 MNCs, the increase in NO is not detectable
(Supplementary material online, Figure S5A). Interferon-g levels in
themediumofMNCsderivedfromCVB3-infectedmiceweresigniﬁ-
cantly induced upon stimulation with inactivated CVB3 and
decreased when MSCs were supplemented (Supplementary
material online, Figure S5B).
Discussion
The ﬁndings of the present study are that MSCs (i) cannot be
infected by CVB3; (ii) reduce direct CVB3-induced cardiomyocyte
injury in an NO-dependent way and require priming by IFN-g, and
(iii) improve experimental murine acute CVB3-induced
myocarditis.
Coxsackievirus B3-induced viral myocarditis, initially considered
a sole immune-mediated disease,
3 also results from a direct
CVB3-mediated injury of the cardiomyocytes in infected
hearts.
1,2 Besides its immunomodulatory effects, MSCs have also
been shown to have anti-apoptotic features. The aim of our
study was to investigate whether MSCs are potential candidates
for the treatment of acute CVB3-induced inﬂammatory cardio-
myopathy. In detail, we analysed whether and how MSCs can (i)
reduce the direct CVB3-mediated cardiomyocyte injury in vitro,
and (ii) decrease cardiac apoptosis and improve LV function in
an experimental model of murine acute CVB3-induced myocar-
ditis. Furthermore, the role of NO and IFN-g priming in the
MSC-mediated protective effects was investigated.
In view of clinical translation, it is a prerequisite that no replica-
tion of CVB3 can take place in MSCs or in any other cell used for
(cardiac) cell therapy. We could demonstrate that MSCs did not
suffer from CVB3 infection and that CVB3 copy number decreased
over time, suggesting that CVB3 did not replicate. Moreover, no
viral progeny release occurred. These ﬁndings are in line with
the described limited expression of the coxsackievirus adenovirus
receptor, which is a critical determinant for cellular uptake and
pathogenesis of CVB3,
26 on MSCs.
27 Furthermore, CVB3 infection
did not alter the beneﬁcial effects of MSCs, suggesting that the
functionality of MSCs upon application in patients with acute
CVB3 infection would not be impaired. Recent studies show that
the protective effects of bone marrow-derived MSCs from patients
with co-morbidities
28,29 are less pronounced compared with those
of MSCs from healthy donors. The investigation of the character-
istics of MSCs from patients with virus-induced inﬂammatory car-
diomyopathy was beyond the scope of this study. The successful
use of allogeneic MSCs in clinical studies for the treatment of non-
cardiac
30 as well as cardiac
8 disorders provides consisting support
to use allogeneic instead of autologous bone marrow-derived
MSCs for the treatment of virus-induced inﬂammatory
cardiomyopathy.
Apoptosis plays an important role in the CVB3 life cycle by facil-
itating viral progeny release and propagation.
31 CVB3 also induces
ROS production, which takes place secondary to virus-induced
apoptosis, following caspase cleavage
32 and can contribute to the
activation of stress-activated protein kinases, which in turn are
required for viral replication and progeny release.
33 In our study,
we found that MSCs signiﬁcantly reduced apoptosis and ROS pro-
duction in HL-1 cells. We suggest that the MSC-mediated decrease
in caspase activity underlies the reduction in ROS. The intracellular
oxidation status has been implicated in the pathogenesis of CVB3
infections
25 by which the ROS-mediated release of host cell
nuclear transcription factor-k-B results in increased viral replica-
tion. Our data indicate that MSCs reduce the intracellular viral pro-
duction, suggesting that the MSC-mediated decrease in ROS
production underlies the reduction in viral replication. Further-
more, MSCs impaired the viral progeny release. Since the intra-
cellular virion particle production affects the amount of viral
particle release, on the one hand, and the liberation of viral par-
ticles requires apoptosis of infected cells,
31 on the other hand,
we suggest that the MSC-mediated decline in cardiomyocyte
ROS production and apoptosis underlies the attenuation in viral
progeny release.
Moreover, we could demonstrate that the anti-apoptotic and
anti-oxidative features of MSCs and their effect on viral progeny
release and viral production were abrogated when MSCs were
pre-treated with the iNOS inhibitor L-NAME, suggesting an
NO-dependent mechanism. This observation is supported by the
Figure 5 Mesenchymal stem cells (MSCs) improve left ventri-
cular function in an experimental model of coxsackievirus
B3-induced myocarditis. Bar graphs represent the mean+SEM
of the contractility parameters (A)d P/dtmax and (B)d P/dtmin in
control (open bar graphs) or coxsackievirus B3-infected (closed
bar graphs) mice injected with PBS or MSCs, with n ¼ 9/group.
S. Van Linthout et al. 2174Figure 6 Mesenchymal stem cells (MSCs) reduce cardiac damage, cardiac apoptosis, and left ventricular tumour necrosis factor-a mRNA
expression levels in an experimental model of coxsackievirus B3 (CVB3)-induced myocarditis. (A) Haematoxylin-and-eosin-stained heart sec-
tions of control mice receiving PBS (Co + PBS; upper left panel) or MSCs (Co + MSC; lower left panel), or of CVB3 infected mice receiving
PBS (CVB3 + PBS; upper right panel) or MSCs (CVB3 + MSC; lower right panel), at a magnification of ×200. (B) Bar graphs represent the
mean+SEM of TUNEL-positive cells per square millimetre in heart cryosections of control mice (open bar), CVB3-infected mice (closed
bar) injected with PBS or MSCs, with n ¼ 10/group. (C) Bar graphs represent the mean+SEM of left ventricular TNF-a mRNA expression
levels normalized towards 18S, of control mice (open bar), CVB3-infected mice (closed bar) injected with PBS or MSCs, with n ¼ 9/group.
MSCs improve murine acute CVB3-induced myocarditis 2175Figure 7 Mesenchymal stem cells (MSCs) decrease cardiac mononuclear cell activation in coxsackievirus B3 (CVB3)-infected mice. (A)
Cardiac mononuclear cells were isolated from control mice receiving PBS (Co + PBS) or MSCs (Co + mesenchymal stem cell), and of
CVB3-infected mice receiving PBS (CVB3 + PBS) or mesenchymal stem cells (CVB3 + MSC). A minimum of n ¼ 8 hearts/group were
pooled to perform the experiment. Next, cardiac mononuclear cells were labelled with 10 mM of carboxyﬂuorescein succinimidyl ester to
be able to measure cell proliferation and cultured for 72 h in the absence (unstimulated; upper panel) or presence of heat-inactivated
CVB3 (stimulated: lower panel), followed by ﬂow cytometry and analysis with FlowJo 8.7. software. Peaks are indicative for the amount of
cell divisions. Representative peaks per group and condition ((un)stimulated) are shown. (B) Mononuclear cells were isolated from the
spleen of control mice (open bar graph) or CVB3-infected (closed bar graph) mice. Next, carboxyﬂuorescein succinimidyl ester-labelled mono-
nuclear cells were directly cultured, in the presence or absence of inactivated CVB3, with or without MSCs (untreated or 24 h pre-treated with
L-NAME), in the presence or absence of 1 mg/mL of anti-murine interferon-g (IFN-g) antibody for 72 h. Then, cells were stained with mono-
clonal anti-CD4 or anti-CD8 antibodies, followed by ﬂow cytometry and analysis with FlowJo 8.7. software. Bar graphs represent the division
index of CD42 (upper panel) and of CD82 T cells (lower panel) with n ¼ 4/group.
S. Van Linthout et al. 2176evidence that stem cells conduct their cardioprotective effects in an
NO-dependent manner,
34 that NO exerts anti-apoptotic effects on
cardiomyocytes,
19,20 and that NO has anti-viral properties.
21,35 In
detail, NO donors have been shown to reduce viral replication
35
and to decrease signs of myocarditis in CVB3-infected mice.
20
Furthermore, the MSC-mediated protective effects were less
pronounced in the presence of a murine anti-IFN-g antibody,
suggesting that MSCs require IFN-g priming to exert their anti-
apoptotic, anti-oxidative, and anti-viral features. This hypothesis
is supported by the ﬁnding that IFN-g is crucial for priming
MSCs to conduct their immunomodulatory effects.
12,17 Further-
more, Oh et al.
18 recently demonstrated that IFN-g is critical for
NO production by MSCs. We could show that supplementation
of IFN-g to CVB3-infected MSCs increased NO vs. non-infected
MSC controls. This suggests that in the context of CVB3 and
upon activation with IFN-g, MSCs produce NO via which they
exert their anti-apoptotic and anti-oxidative effects, leading to a
decrease in viral progeny release and viral production.
Besides priming MSCs, IFN-g has been shown to reduce CVB3
replication and CVB3-induced cytopathogenicity, in part via indu-
cing the release of NO by macrophages.
36,37 However, we can
exclude that the worsened condition of CVB3-infected HL-1 sup-
plemented with an IFN-g antibody and MSCs was due to the
reduced presence of unbound IFN-g, since supplementation of
an IFN-g antibody alone by CVB3 infection was not associated
with an impaired condition of HL1 cells (data not shown).
In vivo, we demonstrated that MSC application resulted in an
improvement in contractility, which was paralleled with an
impaired cardiac damage and cardiac apoptosis, reduced TNF-a
mRNA levels, and cardiac MNC activation. The pathogenesis of
CVB3-induced myocarditis is besides a direct CVB3-induced
injury also characterized by the inﬁltration of inﬂammatory cells,
by which the inﬁltration of T cells coincides with the most
severe acute pathological damage in the myocardium.
38 The
importance of T cells in the severity and development of myocar-
ditis follows from the marked reduction in myocardial damage in
CVB3-infected mice treated with a monoclonal antibody against
total T cells.
39 We foresee that the reduced cardiac injury and
apoptosis in CVB3-infected mice receiving MSCs compared with
PBS are due to the direct anti-apoptotic and anti-viral effects of
MSCs, as shown in vitro, and to MSC-mediated immunomodulatory
effects. Injection of MSCs resulted in a decrease in cardiac mRNA
levels of the pro-inﬂammatory cytokine TNF-a, which is known to
induce cardiomyocyte apoptosis.
40 Furthermore, MSC injection
reduced the activity of cardiac MNCs from CVB3-infected mice.
Since T cells are crucial for the severity of cardiac damage in
CVB3-induced myocarditis,
39 we suggest that the impaired
cardiac MNC activity contributed to the decreased cardiac
damage and apoptosis. In agreement with Ren et al.,
12 we demon-
strated that the MSC-mediated reduction in CVB3-induced CD42
and CD82 T cell proliferation was NO dependent and required
IFN-g priming. The importance of IFN-g priming for the function-
ality of MSCs, on the one hand, and the increased cardiac IFN-g
levels in acute CVB3-induced myocarditis, on the other hand,
41
support the hypothesis that MSCs will exert their protective
effects in the cardiac inﬂammatory environment by acute
CVB3-induced myocarditis.
In conclusion, our data suggest that MSCs have the potential to
be used to treat acute CVB3-induced inﬂammatory cardiomyopa-
thy since MSCs (i) cannot be infected with CVB3, (ii) have anti-
apoptotic and anti-viral effects, and (iii) improve cardiac function
in an experimental model of acute CVB3-induced myocarditis.
However, further investigation is still required to assess the poten-
tial of MSCs for the treatment of chronic CVB3-induced inﬂamma-
tory cardiomyopathy.
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